CALIFORNIA HEART CENTER FOUNDATION: Form 990, tax year 2024

View the entire original 990 at ProPublica ↗

Organization
CALIFORNIA HEART CENTER FOUNDATION (EIN 95-4772979)
Tax period
2024-01-01 to 2024-12-31
Filed
2025-11-11
IRS object ID
202503159349306670
Schema version
2024v5.2
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2025-11-11T18:54:49-06:00ReturnTs
Tax Period End2024-12-31TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN346565596PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1ERNST & YOUNG US LLPBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line118101 VON KARMAN AVENUE SUITE 1700AddressLine1Txt
CityIRVINECityNm
State AbbreviationCAStateAbbreviationCd
ZIP92612ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2024-01-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN954772979EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1CALIFORNIA HEART CENTER FOUNDATIONBusinessNameLine1Txt
FieldValueIRS element (for citing)
Business Name ControlCALIBusinessNameControlTxt
Phone3102488327PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line18670 WILSHIRE BOULEVARD SUITE 301AddressLine1Txt
CityBEVERLY HILLSCityNm
State AbbreviationCAStateAbbreviationCd
ZIP90211ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonJON KOBASHIGAWA MDPersonNm
Person TitlePRESIDENTPersonTitleTxt
Phone3102488327PhoneNum
Signature2025-11-11SignatureDt
Discuss With Paid PreparerYes (1)DiscussWithPaidPreparerInd
FieldValueIRS element (for citing)
IRS Responsible Prty Info CurrYes (1)IRSResponsiblePrtyInfoCurrInd

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonKARA ADAMSPreparerPersonNm
PTINP00023315PTIN
Phone9497942300PhoneNum
FieldValueIRS element (for citing)
Tax2024TaxYr
Build TS2025-03-06 01:10:19ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Principal OfficerJON KOBASHIGAWA MDPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line18670 WILSHIRE BOULEVARD SUITE 301AddressLine1Txt
CityBEVERLY HILLSCityNm
State AbbreviationCAStateAbbreviationCd
ZIP90211ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$2,858,458GrossReceiptsAmt
Group Return For Affiliates0GroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.CALHEART.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation2000FormationYr
Legal Domicile StateCALegalDomicileStateCd
Activity Or MissionPROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE.ActivityOrMissionDesc
Voting Members Governing Body5VotingMembersGoverningBodyCnt
Voting Members Independent3VotingMembersIndependentCnt
Total Employee0TotalEmployeeCnt
Total Volunteers0TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm$0NetUnrelatedBusTxblIncmAmt
PY Contributions Grants$2,875,537PYContributionsGrantsAmt
CY Contributions Grants$2,115,128CYContributionsGrantsAmt
PY Program Service Revenue$373,961PYProgramServiceRevenueAmt
CY Program Service Revenue$743,330CYProgramServiceRevenueAmt
PY Investment Income$0PYInvestmentIncomeAmt
CY Investment Income$0CYInvestmentIncomeAmt
PY Other Revenue$0PYOtherRevenueAmt
CY Other Revenue$0CYOtherRevenueAmt
PY Total Revenue$3,249,498PYTotalRevenueAmt
CY Total Revenue$2,858,458CYTotalRevenueAmt
PY Grants And Similar Paid$0PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$5,000CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members$0PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$2,453,159PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$2,156,580CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$0PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$0CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$0CYTotalFundraisingExpenseAmt
PY Other Expenses$684,558PYOtherExpensesAmt
CY Other Expenses$615,798CYOtherExpensesAmt
PY Total Expenses$3,137,717PYTotalExpensesAmt
CY Total Expenses$2,777,378CYTotalExpensesAmt
PY Revenues Less Expenses$111,781PYRevenuesLessExpensesAmt
CY Revenues Less Expenses$81,080CYRevenuesLessExpensesAmt
Total Assets BOY$984,084TotalAssetsBOYAmt
Total Assets EOY$843,523TotalAssetsEOYAmt
Total Liabilities BOY$284,091TotalLiabilitiesBOYAmt
Total Liabilities EOY$62,450TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$699,993NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$781,073NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionTHE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES.MissionDesc
Significant New Program Srvc0SignificantNewProgramSrvcInd
Significant Change0SignificantChangeInd
Expense$2,503,870ExpenseAmt
Grant$5,000GrantAmt
Revenue$743,330RevenueAmt
DescTHE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2024: SCIENTIFIC FORUMS AND EDUCATIONAL ACTIVITIES:* "SUCCESS WITH FAILURE: AN ADVANCED HEART DISEASE SYMPOSIUM" FEBRUARY 9TH, 2024 (CULVER CITY)THIS 1-DAY SYMPOSIUM ON ADVANCED HEART DISEASE TOOK PLACE ON FRIDAY, FEBRUARY 9TH, 2024 AT THE HILTON CULVER CITY. THE SYMPOSIUM PROVIDED AN IN-DEPTH REVIEW OF DIAGNOSTICS, THERAPEUTIC OPTIONS AND NOVEL TREATMENTS IN ADVANCED HEART FAILURE, MECHANICAL CIRCULATORY SUPPORT AND TRANSPLANTATION. THE PROGRAM DREW 176 ATTENDEES CONSISTING OF PHYSICIANS, ALLIED HEALTH PROFESSIONALS, INCLUDING NURSE PRACTITIONERS, TRANSPLANT COORDINATORS, PHYSICIAN ASSISTANTS, RNS AND CASE MANAGERS FROM ACROSS CALIFORNIA.* "AST FORUM: FELLOWSHIP TASK FORCE" FEBRUARY 24TH, 2024 (ARIZONA)SPONSORED AND HOSTED BY THE AMERICAN SOCIETY OF TRANSPLANTATION, THE AST FELLOWSHIP TASK FORCE FORUM WAS DESIGNED TO PROVIDE A PLATFORM FOR AN IN-DEPTH DISCUSSION ON THE CULTIVATION AND DEVELOPMENT OF TRAINEES. TO INCLUDE KEY STAKEHOLDERS IN ALL SOLID ORGAN TRANSPLANTATION (HEART, LUNG, LIVER, KIDNEY), THE MEETING FACILITATED A REVIEW OF FACTORS IMPACTING TRAINEES AND IDENTIFIED POTENTIAL INTERVENTIONS TO FURTHER PROMOTE THE FIELD. THE HOPE IS THAT THIS CONFERENCE WILL BE A FIRST STEP IN DEVELOPING A "TOOL KIT" TO ADDRESS BARRIERS AND CONCERNS THAT MAY INHIBIT THE PURSUIT OF SPECIALIZATION IN TRANSPLANTATION THAT CAN BE LEVERAGED BY INDIVIDUALS, INSTITUTIONS, AND ALLIED TRANSPLANT COMMUNITY GROUPS. (PUBLICATION OF MEETING REPORT PENDING.)* "CONSENSUS CONFERENCE: PRIMARY GRAFT DYSFUNCTION" APRIL 9TH, 2024 (PRAGUE)SPONSORED JOINTLY BY THE INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION AND THE CALIFORNIA HEART CENTER/CEDARS-SINAI HEART INSTITUTE, THE 2024 CONSENSUS CONFERENCE ON PRIMARY GRAFT DYSFUNCTION WAS DESIGNED TO PROVIDE A FORUM FOR AN IN-DEPTH DISCUSSION AMONG THE LEADING EXPERTS IN THE FIELD, WITH A VIEW TO EVALUATING EVOLVING SCIENCE IN THIS AREA, AS PART OF AN UPDATE TO THE 2013 ISHLT CONSENSUS CONFERENCE ON PGD. THE HOPE IS THAT THIS CONFERENCE WILL PROVIDE A FORUM TO PROVIDE FURTHER GUIDANCE ON THE EFFICACY OF TREATMENT OPTIONS FOR PRIMARY GRAFT DYSFUNCTION, THE UTILITY OF RISK STRATIFICATION FOR PGD USING VARIOUS METHODOLOGIES, AND THE POTENTIAL OF REDUCING THE RISK OF PGD WITH THE ADVENT OF NEW TECHNOLOGIES FOR PROCUREMENT AND PRESERVATION OF DONOR HEARTS. (PUBLICATION OF CONSENSUS REPORT PENDING.)* "THOMAS D. GORDON VISITING PROFESSOR IN ADVANCED HEART DISEASE" OCTOBER 14TH-15TH, 2024. THIS ANNUAL VISITING PROFESSORSHIP HAS CONTINUED TO BE SPONSORED AND ORGANIZED BY DR. KOBASHIGAWA. THIS YEAR THE ORGANIZATION HAD THE HONOR OF HOSTING DR. ANDREAS ZUCKERMANN, INTERNATIONALLY RENOWNED CARDIOTHORACIC SURGEON AND DIRECTOR OF CARDIAC TRANSPLANTATION AT MEDICAL UNIVERSITY OF VIENNA. THIS VISIT, HELD OCTOBER 14TH-15TH, 2024 INCLUDED A GRAND ROUNDS LECTURE, ONE TO ONE FACULTY MEETINGS AND A FELLOWS' PROFESSIONAL DEVELOPMENT DISCUSSION. DR. ZUCKERMANN'S LECTURE ON "EX VIVO PERFUSION" WAS EXTREMELY WELL RECEIVED.* SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF DR. JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS HAVE BEEN OFFERED TO STUDENTS FOR THE SUMMER OF 2024. THESE INTERNSHIPS PROVIDE STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WERE SUBMITTED TO THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. THIS YEAR'S GROUP INCLUDES STUDENTS FROM:OHIO STATE UNIVERSITYPURDUE UNIVERSITYUNIVERSITY OF CALIFORNIA, BERKLEYUNIVERSITY OF CALIFORNIA, IRVINEUNIVERSITY OF CALIFORNIA, LOS ANGELESUNIVERSITY OF COLORADOUNIVERSITY OF SOUTHERN CALIFORNIA* HEART TRANSPLANT JOURNAL CLUBSJOURNAL CLUBS CONTINUE TO BE HELD IN A VIRTUAL FORMAT AND HAVE MAINTAINED STRONG PARTICIPATION, WITH AN AVERAGE ATTENDANCE OF 25 PEOPLE AT EACH SESSION. THE FOLLOWING SESSION(S) HAVE BEEN IMPLEMENTED OR SCHEDULED: MARCH 14TH, 2024 - 4:00PM - 5:00PM "DEVELOPMENT AND VALIDATION OF A RISK SCORE PREDICTING DEATH WITHOUT TRANSPLANT IN ADULT HEART TRANSPLANT CANDIDATES" PRESENTER: DR. ISABEL BALACHANDRAN CLINICAL RESEARCH:THIS SECTION IS FORMATTED BY CATEGORY; STUDY NAME; PRINCIPAL INVESTIGATOR (PI).Desc
Total Program Service Expenses$2,503,870TotalProgramServiceExpensesAmt
Described In Section501c3Yes (1)DescribedInSection501c3Ind
Schedule B RequiredYes (1)ScheduleBRequiredInd
Political Campaign Acty0PoliticalCampaignActyInd
Lobbying Activities0LobbyingActivitiesInd
Subject To Proxy Tax0SubjectToProxyTaxInd
Donor Advised Fund0DonorAdvisedFundInd
Conservation Easements0ConservationEasementsInd
Collections Of Art0CollectionsOfArtInd
Credit Counseling0CreditCounselingInd
Donor Rstr Or Quasi Endowments0DonorRstrOrQuasiEndowmentsInd
Report Land Building EquipmentYes (1)ReportLandBuildingEquipmentInd
Report Investments Other Sec0ReportInvestmentsOtherSecInd
Report Program Related Invst0ReportProgramRelatedInvstInd
Report Other Assets0ReportOtherAssetsInd
Report Other Liabilities0ReportOtherLiabilitiesInd
Include FIN48 Footnote0IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt0IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt0ConsolidatedAuditFinclStmtInd
School Operating0SchoolOperatingInd
Foreign Office0ForeignOfficeInd
Foreign Activities0ForeignActivitiesInd
More Than5000 K To Org0MoreThan5000KToOrgInd
More Than5000 K To Individuals0MoreThan5000KToIndividualsInd
Professional Fundraising0ProfessionalFundraisingInd
Fundraising Activities0FundraisingActivitiesInd
Gaming Activities0GamingActivitiesInd
Operate Hospital0OperateHospitalInd
Grants To Organizations0GrantsToOrganizationsInd
Grants To Individuals0GrantsToIndividualsInd
Schedule J RequiredYes (1)ScheduleJRequiredInd
Tax Exempt Bonds0TaxExemptBondsInd
Engaged In Excess Benefit Trans0EngagedInExcessBenefitTransInd
PY Excess Benefit Trans0PYExcessBenefitTransInd
Loan Outstanding0LoanOutstandingInd
Grant To Related Person0GrantToRelatedPersonInd
Business Rln With Org Mem0BusinessRlnWithOrgMemInd
Business Rln With Fam Mem0BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent0BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri0DeductibleNonCashContriInd
Deductible Art Contribution0DeductibleArtContributionInd
Terminate Operations0TerminateOperationsInd
Partial Liquidation0PartialLiquidationInd
Disregarded Entity0DisregardedEntityInd
Related EntityYes (1)RelatedEntityInd
Related Organization Ctrl EntYes (1)RelatedOrganizationCtrlEntInd
Transaction With Control Ent0TransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org0TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp0ActivitiesConductedPrtshpInd
Schedule O RequiredYes (1)ScheduleORequiredInd
IRP Document0IRPDocumentCnt
IRP Document W2 G0IRPDocumentW2GCnt
Employee0EmployeeCnt
Unrelated Bus Incm Over Limit0UnrelatedBusIncmOverLimitInd
Foreign Financial Account0ForeignFinancialAccountInd
Prohibited Tax Shelter Trans0ProhibitedTaxShelterTransInd
Taxable Party Notification0TaxablePartyNotificationInd
Nondeductible Contributions0NondeductibleContributionsInd
Quid Pro Quo Contributions0QuidProQuoContributionsInd
Form8282 Property Disposed Of0Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct0RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct0PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services0IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt0SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc0SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members5GoverningBodyVotingMembersCnt
Independent Voting Member3IndependentVotingMemberCnt
Family Or Business Rln0FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties0DelegationOfMgmtDutiesInd
Change To Org Documents0ChangeToOrgDocumentsInd
Material Diversion Or Misuse0MaterialDiversionOrMisuseInd
Members Or StockholdersYes (1)MembersOrStockholdersInd
Election Of Board MembersYes (1)ElectionOfBoardMembersInd
Decisions Subject To ApprovaYes (1)DecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (1)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (1)MinutesOfCommitteesInd
Officer Mailing Address0OfficerMailingAddressInd
Local Chapters0LocalChaptersInd
Form990 Provided To Gvrn Body0Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (1)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (1)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (1)RegularMonitoringEnfrcInd
Whistleblower Policy0WhistleblowerPolicyInd
Document Retention Policy0DocumentRetentionPolicyInd
Compensation Process CEO0CompensationProcessCEOInd
Compensation Process OtherYes (1)CompensationProcessOtherInd
Investment In Joint Venture0InvestmentInJointVentureInd
States Where Copy Of Return Is FldCAStatesWhereCopyOfReturnIsFldCd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1DEBBIE BOTTENBusinessNameLine1Txt
FieldValueIRS element (for citing)
Phone3104238473PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line16500 WILSHIRE BLVD 19TH FLOORAddressLine1Txt
CityLOS ANGELESCityNm
State AbbreviationCAStateAbbreviationCd
ZIP90048ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (12 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtAverage Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRtIndividual Trustee Or DirectorIndividualTrusteeOrDirectorIndOfficerOfficerIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtHighest Compensated EmployeeHighestCompensatedEmployeeIndFormer Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd
JON KOBASHIGAWA MD
PRESIDENT2.000.00Yes (X)Yes (X)$0$0$0
MICHELE HAMILTON
TREASURER2.000.00Yes (X)Yes (X)$0$0$0
THOMAS D GORDON
DIRECTOR1.002.00Yes (X)$0$84,000$0
EDUARDO MARBAN MD
DIRECTOR1.0050.00Yes (X)$0$4,147,273$397,688
JAIME MORIGUCHI MD
DIRECTOR1.000.00Yes (X)$0$0$0
CHRISTINE SUMBI
SECRETARY40.000.00Yes (X)$0$264,422$37,095
SHRUTI SHANTHARAM
DIRECTOR, RESEARCH OPERATIONS40.000.00$0$192,467$13,967Yes (X)
ADAM DANIELS
RESEARCH NURSE PRACTITIONER40.000.00$0$172,645$13,892Yes (X)
VENISE STRAND
PROGRAM MANAGER40.000.00$0$136,716$42,955Yes (X)
PHYLLIS KATZ
EXECUTIVE ASSISTANT40.000.00$0$124,857$21,563Yes (X)
SAVANNAH MERSOLA
RESEARCH SPECIALIST40.000.00$0$119,048$17,119Yes (X)
IRINA COZIANU
FORMER HIGHEST COMPENSATED40.000.00$0$128,493$35,793Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$0TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org$5,369,921TotReportableCompRltdOrgAmt
Total Other Compensation$580,072TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K0IndivRcvdGreaterThan100KCnt
Former Ofcr Employees ListedYes (1)FormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (1)TotalCompGreaterThan150KInd
Compensation From Other Srcs0CompensationFromOtherSrcsInd
Cntrct Rcvd Greater Than100 K0CntrctRcvdGreaterThan100KCnt
Related Organizations$2,115,128RelatedOrganizationsAmt
Total Contributions$2,115,128TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

FieldValueIRS element (for citing)
DescEDUCATIONAL PROGRAMSDesc
Business611430BusinessCd
Total Revenue Column$743,330TotalRevenueColumnAmt
Related Or Exempt Func Income$743,330RelatedOrExemptFuncIncomeAmt
FieldValueIRS element (for citing)
Total Program Service Revenue$743,330TotalProgramServiceRevenueAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$2,858,458TotalRevenueColumnAmt
Related Or Exempt Func Income$743,330RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$0ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

FieldValueIRS element (for citing)
Total$5,000TotalAmt
Program Services$5,000ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$270,231TotalAmt
Management And General$270,231ManagementAndGeneralAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$1,249,575TotalAmt
Program Services$1,249,575ProgramServicesAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$636,774TotalAmt
Program Services$636,774ProgramServicesAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$1,503TotalAmt
Program Services$1,052ProgramServicesAmt
Management And General$451ManagementAndGeneralAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$6,590TotalAmt
Program Services$5,931ProgramServicesAmt
Management And General$659ManagementAndGeneralAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$514,096TotalAmt
Program Services$514,096ProgramServicesAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$43,344TotalAmt
Program Services$41,177ProgramServicesAmt
Management And General$2,167ManagementAndGeneralAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$29,438TotalAmt
Program Services$29,438ProgramServicesAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDescTotalTotalAmtProgram ServicesProgramServicesAmt
DUES & SUBSCRIPTIONS$10,057$10,057
BANK CHARGES$4,509$4,509
RENT/LEASE - EQUIPMENT$1,886$1,886
REPAIR & MAINTENANCE$1,173$1,173

All Other Expenses AllOtherExpensesGrp

FieldValueIRS element (for citing)
Total$3,202TotalAmt
Program Services$3,202ProgramServicesAmt

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$2,777,378TotalAmt
Program Services$2,503,870ProgramServicesAmt
Management And General$273,508ManagementAndGeneralAmt
Fundraising$0FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$401,818BOYAmt
EOY$418,723EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$398BOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$581,134LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$173,913LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$436,659BOYAmt
EOY$407,221EOYAmt

Other Assets Total OtherAssetsTotalGrp

FieldValueIRS element (for citing)
BOY$145,209BOYAmt
EOY$17,579EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$984,084BOYAmt
EOY$843,523EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$284,091BOYAmt
EOY$62,450EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$284,091BOYAmt
EOY$62,450EOYAmt
FieldValueIRS element (for citing)
Organization Follows FASB117Yes (X)OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$699,993BOYAmt
EOY$781,073EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$699,993BOYAmt
EOY$781,073EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$984,084BOYAmt
EOY$843,523EOYAmt
FieldValueIRS element (for citing)
Reconcilation Revenue Expnss$81,080ReconcilationRevenueExpnssAmt
Other Changes In Net Assets$0OtherChangesInNetAssetsAmt
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or Review0AccountantCompileOrReviewInd
FS Audited0FSAuditedInd
Federal Grant Audit Required0FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$2,136,097CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$2,100,269CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$2,935,423CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$2,875,537CurrentTaxYearMinus1YearAmt
Current Tax Year$2,115,128CurrentTaxYearAmt
Total$12,162,454TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$2,136,097CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$2,100,269CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$2,935,423CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$2,875,537CurrentTaxYearMinus1YearAmt
Current Tax Year$2,115,128CurrentTaxYearAmt
Total$12,162,454TotalAmt
FieldValueIRS element (for citing)
Public Support Total170$12,162,454PublicSupportTotal170Amt
Total Support$12,162,454TotalSupportAmt
Gross Receipts Rltd Activities$1,907,038GrossReceiptsRltdActivitiesAmt
Public Support CY1701.00000PublicSupportCY170Pct
Public Support PY1701.00000PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

FieldValueIRS element (for citing)
ContributorRESTRICTEDContributorNum

Contributor Business Name ContributorBusinessName

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor US Address ContributorUSAddress

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Total ContributionsRESTRICTEDTotalContributionsAmt

Schedule D IRS990ScheduleD

Leasehold Improvements LeaseholdImprovementsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$473,456OtherCostOrOtherBasisAmt
Depreciation$66,235DepreciationAmt
Book Value$407,221BookValueAmt

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$70,594OtherCostOrOtherBasisAmt
Depreciation$70,594DepreciationAmt
Book Value$0BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$37,084OtherCostOrOtherBasisAmt
Depreciation$37,084DepreciationAmt
Book Value$0BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$407,221TotalBookValueLandBuildingsAmt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Severance Payment0SeverancePaymentInd
Supplemental Nonqual Rtr PlanYes (1)SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm0EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org0CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs0CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org0CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs0CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments0AnyNonFixedPaymentsInd
Initial Contract Exception0InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (6 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtCompensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmtBonus Filing OrganizationBonusFilingOrganizationAmountBonus Related OrganizationsBonusRelatedOrganizationsAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtOther Compensation Rltd OrgsOtherCompensationRltdOrgsAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtDeferred Comp Rltd OrgsDeferredCompRltdOrgsAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtNontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtTotal Compensation Rltd OrgsTotalCompensationRltdOrgsAmtComp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmtComp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
EDUARDO MARBAN MD
DIRECTOR$0$2,594,572$0$579,284$0$973,417$0$358,833$0$38,855$0$4,544,961$0$0
CHRISTINE SUMBI
SECRETARY$0$221,243$0$34,846$0$8,333$0$21,364$0$15,731$0$301,517$0$0
SHRUTI SHANTHARAM
DIRECTOR, RESEARCH OPERATIONS$0$164,624$0$27,828$0$15$0$5,820$0$8,147$0$206,434$0$0
ADAM DANIELS
RESEARCH NURSE PRACTITIONER$0$163,047$0$9,416$0$182$0$5,509$0$8,383$0$186,537$0$0
VENISE STRAND
PROGRAM MANAGER$0$120,106$0$16,461$0$149$0$12,866$0$30,089$0$179,671$0$0
IRINA COZIANU
FORMER HIGHEST COMPENSATED$0$123,215$0$1,235$0$4,043$0$7,495$0$28,298$0$164,286$0$0

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
PART I, LINE 3PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, SECTION B LINE 15B.
PART I, LINE 4BTHE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. THE FOLLOWING DIRECTOR AND OFFICER RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2024: CHRISTINE SUMBI 7,845 EDUARDO MARBAN, MD 802,184

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (9 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PART III, LINE 4A(CONTINUED) AMYLOIDOSIS; PHASE 3 GLOBAL, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION-682884 IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM); PATEL AMYLOIDOSIS; APOLLO-B: A STUDY TO EVALUATE PATISIRAN IN PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY (ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY); PATEL AMYLOIDOSIS; EIDOS -AG310-301 (A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF AG10 IN SUBJECTS WITH SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTRIBUTE-CM TRIAL)); PATEL AMYLOIDOSIS; CARDIAC AMYLOIDOSIS REGISTRY STUDY (MULTI-CENTER); PATEL AMYLOIDOSIS; AMYLOIDOSIS SURVEY; PATEL HEART FAILURE; A DOUBLE-BLIND, RANDOMIZED, SHAM-PROCEDURE-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF ALLOGENEIC MESENCHYMAL PRECURSOR CELLS (REXLEMESTROCEL-L) IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION OF EITHER ISCHEMIC OR NONISCHEMIC ETIOLOGY; CHANG HEART FAILURE; BARIATRIC SURGERY AND HEART FAILURE; HAMILTON HEART FAILURE; REDUCING LUNG CONGESTION SYMPTOMS USING THE V-WAVE SHUNT IN HEART FAILURE (RELIEVE HF); HAMILTON HEART FAILURE; RISK FACTORS AND OUTCOMES IN ADVANCED HEART DISEASE; KOBASHIGAWA HEART FAILURE; DCM PRECISION MEDICINE STUDY; KRANSDORF HEART FAILURE; DILATED CARDIOMYOPATHY PRECISION MEDICINE STUDY - CARDIAC MRI SUBSTUDY; KRANSDORF HEART TRANSPLANT; OCS HEART PERFUSION POST-APPROVAL REGISTRY OCS HEART PERFUSION POST- APPROVAL REGISTRY PROTOCOL; ESMAILIAN HEART TRANSPLANT; DCD-IIT EVALUATING THE SAFETY OF UTILIZING DONOR HEARTS FROM DONATION AFTER CIRCULATORY DEATH (DCD) DONORS COMPARED TO DONOR HEARTS FROM DONATION AFTER BRAIN DEATH (DBD) DONORS: A SINGLE CENTER PILOT STUDY; ESMAILIAN HEART TRANSPLANT; RANDOMIZED TRIAL TO COMPARE THE SHERPAPAK DEVICE VS COLD STORAGE OF DONOR HEARTS IN TRANSPLANTATION: A PILOT STUDY; ESMAILIAN HEART TRANSPLANT; THE FREQUENCY AND SIGNIFICANCE OF BLOOD TYPE A1 DONORS TO NON-A1 SUBGROUP RECIPIENTS IN HEART TRANSPLANTATION; KITTLESON HEART TRANSPLANT; ATG (A PILOT RANDOMIZED STUDY TO ASSESS THE EFFECT AND SAFETY PROFILE OF THYMOGLOBULIN IN PRIMARY CARDIAC TRANSPLANT RECIPIENTS: A 12-MONTH, SINGLE CENTER, RANDOMIZED, OPEN-LABEL STUDY OF EFFICACY COMPARING IMMEDIATE TREATMENT WITH AND WITHOUT THYMOGLOBULIN 1.5 MG/KG/D FOR 5 CONSECUTIVE DAYS IN HEART TRANSPLANT RECIPIENTS); KOBASHIGAWA HEART TRANSPLANT; SHORE (SURVEILLANCE HEARTCARE OUTCOMES REGISTRY); KOBASHIGAWA HEART TRANSPLANT; COMPUTER ASSISTED CARDIAC HISTOLOGIC EVALUATION; KOBASHIGAWA HEART TRANSPLANT; TARGETING INFLAMMATION AND ALLOIMMUNITY IN HEART TRANSPLANT RECIPIENTS WITH TOCILIZUMAB; KOBASHIGAWA AND PATEL HEART TRANSPLANT; INFILTRATING B CELLS IN CARDIAC ALLOGRAFT VASCULOPATHY; KRANSDORF HEART TRANSPLANT; IMMUNOLOGIC RISK STUDY; KRANSDORF HEART TRANSPLANT; DEVELOPMENT OF NON-INVASIVE CELL-FREE DNA TO SUPPLANT INVASIVE BIOPSY IN HEART TRANSPLANTATION-DEFINE-HT; KRANSDORF PULMONARY HYPERTENSION; RIOCIGUAT USERS REGISTRY - THE ROAR REGISTRY; HAGE PULMONARY HYPERTENSION; RIN-PH-304: PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROSTINIL IN PATIENTS WITH PULMONARY HYPERTENSION DUE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE (PH-COPD); HAGE PULMONARY HYPERTENSION; AN OBSERVATIONAL STUDY TO CHARACTERIZE PATIENT GLOBAL IMPRESSION QUESTIONS FOR ACTIVITY-INDUCED SYMPTOMS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION; HAGE HEART TRANSPLANT; ARTORIA STUDY: AN OBSERVATIONAL STUDY REGARDING THE OUTCOME OF ADULT PATIENTS WITH CONGENITAL HEART DISEASE (ACHD) OR INHERITED CARDIOMYOPATHIES UNDERGOING HEART OR HEART/LUNG TRANSPLANTATION; KOBASHIGAWA AMYLOIDOSIS; ALYNAM - ALN-TTR02-014 EXPANDED ACCESS PROTOCOL TO PROVIDE PATISIRAN TO PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR AMYLOIDOSIS) WITH CARDIOMYOPATHY; PATEL HEART FAILURE; NOVONORDISK NN6019-4940: EFFICACY AND SAFETY OF NNC6019-0001 AT TWO DOSE LEVELS IN PARTICIPANTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR CM); COLE PULMONARY HYPERTENSION; CADENCE - A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF SOTATERCEPT VERSUS PLACEBO FOR THE TREATMENT OF COMBINED POSTCAPILLARY AND PRECAPILLARY PULMONARY HYPERTENSION (CPC-PH) DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF); HAGE HEART FAILURE; G-COR STUDY: GLOBAL CARDIO ONCOLOGY REGISTRY PROTOCOL; NIKOLOVA PULMONARY HYPERTENSION; INSMED_INS1009-202 A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF TREPROSTINIL PALMITIL INHALATION POWDER IN PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION; HAGE PULMONARY HYPERTENSION; INSMED_INS1009-203 AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF THE LONG-TERM USE OF TREPROSTINIL PALMITIL INHALATION POWDER IN PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION; HAGE PULMONARY HYPERTENSION; ASTRAZENECA_D8330C00003 A PHASE IIB RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTRE, DOSE-RANGING STUDY OF AZD3427 IN PARTICIPANTS WITH HEART FAILURE AND PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE (WHO GROUP 2); HAGE AMYLOID; ATTR IN LSS ANALYSIS OF LUMBAR SPINE STENOSIS SPECIMENS FOR IDENTIFICATION OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS; KITTLESON HEART TRANSPLANT; PREGNANCY SURVEY PATIENT EDUCATION REGARDING PREGNANCY AFTER HEART TRANSPLANTATION; KITTLESON HEART TRANSPLANT; COVID VACCINATION STUDY ASSESSING THE CELLULAR AND HUMORAL RESPONSE TO SARS-COV-2 (COVID-19) VACCINATION IN HEART TRANSPLANT RECIPIENTS; KRANSDORF HEART FAILURE; CAV INFILTRATING B CELLS IN CARDIAC ALLOGRAFT VASCULOPATHY; KRANSDORF HEART FAILURE; IPSC STUDY INDUCED PLURIPOTENT STEM CELL CARDIOMYOCYTE; KRANSDORF PULMONARY HYPERTENSION; REM-PH-418_ARTISAN A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION); GEFT HEART TRANSPLANT; OPEN-LABEL TAFAMIDIS ATTR AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF TAFAMIDIS IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS POST ORTHOTOPIC HEART TRANSPLANTATION; STERN HEART FAILURE; ECHONET SCREENING STUDY ARTIFICIAL INTELLIGENCE GUIDED ECHOCARDIOGRAPHIC SCREENING OF RARE DISEASES; STERN AMYLOID; AMYLOIDOSIS SURVEY IDENTIFYING AN ASSOCIATION BETWEEN ATHLETIC ACTIVITY AND CARDIAC AMYLOIDOSIS; STERN HEART TRANSPLANT; DSA PROJECT FUNCTIONAL CHARACTERIZATION OF POST HEART TRANSPLANT DE NOVO DONOR SPECIFIC ANTIBODIES (DNDSAS); NIKOLOVA HEART TRANSPLANT; ION-682884-CS12_OLE AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY OF EPLONTERSEN (ION-682884) IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM); NIKOLOVA HEART TRANSPLANT; G-COR GLOBAL CARDIO ONCOLOGY REGISTRY; NIKOLOVA HEART FAILURE; NOVONORDISK NN6019-7565 OPEN-LABEL EXTENSION STUDY OF LONG-TERM SAFETY AND EFFICACY OF NNC6019-0001 IN PARTICIPANTS WITH TRANSTHRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM); COLE
FORM 990, PART IV, LINE 12THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/24 AND 6/30/25 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/24.
FORM 990, PART VI, SECTION A, LINE 6CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION.
FORM 990, PART VI, SECTION A, LINE 7ACEDARS-SINAI MEDICAL CENTER, AS THE SOLE CORPORATE MEMBER, ELECTS BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION.
FORM 990, PART VI, SECTION A, LINE 7BRESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX-EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; AND (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION.
FORM 990, PART VI, SECTION B, LINE 11BTHE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM.
FORM 990, PART VI, SECTION B, LINE 12CCONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION.
FORM 990, PART VI, SECTION B, LINE 15BTHE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S OFFICERS AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT WITH RESPECT TO SUCH ISSUES. THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S OFFICERS AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT, AND ANY OTHER ADVISORS IT DEEMS NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS.
FORM 990, PART VI, SECTION C, LINE 19THE ORGANIZATION'S CONFLICT OF INTEREST POLICY AND GOVERNING DOCUMENTS ARE NOT AVAILABLE TO THE PUBLIC AND ITS TAX-EXEMPT PARENT'S AUDITED CONSOLIDATED FINANCIAL STATEMENTS ARE ATTACHED TO THE PARENT'S FORM 990.

Schedule R IRS990ScheduleR

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (13 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdExempt Code SectionExemptCodeSectionTxtPublic Charity StatusPublicCharityStatusTxtBusiness Name Line1DirectControllingEntityName/BusinessNameLine1TxtControlled OrganizationControlledOrganizationIndDirect Controlling NADirectControllingNACd
CEDARS-SINAI MEDICAL CENTER
8700 BEVERLY BOULEVARDLOS ANGELESCA90048951644600ACUTE-CARE, TEACHING AND RESEARCH HOSPITALCA501(C)(3)LINE 3CEDARS-SINAI HEALTH SYSTEM0
CEDARS-SINAI MEDICAL CARE FOUNDATION
6500 WILSHIRE BLVD 19TH FLOORLOS ANGELESCA90048954457756PROVISION OF MEDICAL CARE, TEACHING AND RESEARCHCA501(C)(3)LINE 12A, ICEDARS-SINAI MEDICAL CENTERYes (1)
KERLAN-JOBE ORTHOPAEDIC FOUNDATION
6801 PARK TERRACE 500LOS ANGELESCA90045954707606EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC MEDICINECA501(C)(3)LINE 7CEDARS-SINAI MEDICAL CARE FOUNDATIONYes (1)
SANTA MONICA ORTHOPAEDIC & SPORTS MED RESEARCH FDN
2020 SANTA MONICA BLVD 4TH FLRSANTA MONICACA90404954789926EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC AND NEUROLOGIC CONDITIONSCA501(C)(3)PFCEDARS-SINAI MEDICAL CARE FOUNDATIONYes (1)
CEDARS-SINAI MARINA HOSPITAL
4650 LINCOLN BLVDMARINA DEL REYCA90292201645949HEALTH SERVICESCA501(C)(3)LINE 3CEDARS-SINAI MEDICAL CENTERYes (1)
CEDARS-SINAI HEALTH SYSTEM
6500 WILSHIRE BLVD SUITE 2400LOS ANGELESCA90048300990905SUPPORT SPECIFIED NONPROFIT HEALTHCARE ORGANIZATIONSCA501(C)(3)LINE 12C, III-FI0N/A
TORRANCE HEALTH ASSOCIATION
3330 LOMITA BLVDTORRANCECA90505330073515HEALTH SERVICESCA501(C)(3)LINE 12B, IICEDARS-SINAI HEALTH SYSTEMYes (1)
TORRANCE MEMORIAL MEDICAL CENTER HEALTH CARE FOUNDATION
3330 LOMITA BLVDTORRANCECA90505953528452FUNDRAISINGCA501(C)(3)LINE 7TORRANCE HEALTH ASSOCIATIONYes (1)
TORRANCE MEMORIAL MEDICAL CENTER
3330 LOMITA BLVDTORRANCECA90505951644042HEALTH SERVICESCA501(C)(3)LINE 3TORRANCE HEALTH ASSOCIATIONYes (1)
CEDARS SINAI INTELLECTUAL PROPERTY COMPANY
8700 BEVERLY BOULEVARDLOS ANGELESCA90048871097792MANAGEMENT AND LICENSING OF INTELLECTUAL PROPERTY ASSETSCA501(C)(3)12A, ICEDARS-SINAI MEDICAL CENTERYes (1)
PASADENA HOSPITAL ASSOCIATION LTD
100 WEST CALIFORNIA BLVDPASADENACA91105951644036HEALTH SERVICESCA501(C)(3)LINE 3CEDARS-SINAI HEALTH SYSTEMYes (1)
HUNTINGTON MEDICAL FOUNDATION
100 WEST CALIFORNIA BLVDPASADENACA91105954434428HEALTH SERVICESCA501(C)(3)LINE 3PASADENA HOSPITAL ASSOCIATION LTDYes (1)
CEDARS SINAI HEALTH VENTURES
8700 BEVERLY BLVDLOS ANGELESCA90048883506667MANAGEMENT OF HEALTH INNOVATIONSCA501(C)(3)12A, ICEDARS-SINAI MEDICAL CENTERYes (1)

Id Related Org Txbl Partnership IdRelatedOrgTxblPartnershipGrp (12 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdDirect Controlling NADirectControllingNACdDisproportionate AllocationsDisproportionateAllocationsIndGeneral Or Managing PartnerGeneralOrManagingPartnerInd
ENDOSCOPY CENTER OF SANTA MONICA LLC
12400 WILSHIRE BLVD SUITE 100LOS ANGELESCA90025113652210ENDOSCOPIES AND RELATED PROCEDURESCAN/A00
ISS ASC HOLDINGS LLC
6500 WILSHIRE BLVD 19TH FLOORLOS ANGELESCA90048471890805INVESTMENT IN HEALTHCARE SERVICESCAN/A00
CS-BH ASC HOLDINGS LLC
450 N ROXBURY DR SUITE 602BEVERLY HILLSCA90210812246488HOLDING COMPANYCAN/A00
INTERNATIONAL SPINE & ORTHOPEDIC INSTITUTE LLC
8500 W 110TH STOVERLAND PARKKS66210263738893SPINE AND ORTHOPEDIC INSTITUTEDEN/A00
SANTA MONICA IMAGING GROUP LLC
6500 WILSHIRE BLVD 19TH FLOORLOS ANGELESCA90048820760657IMAGING CENTERCAN/A00
TORRANCE MEMORIAL SURGICAL CENTER LLC I
23560 CRENSHAW BLVD SUITE 104TORRANCECA90505465259260OUTPATIENT SURGICAL SERVICESCAN/A00
3565 DEL AMO ASSOCIATES A CALIFORNIA LIMITED PARTNERSHIP
5017 CARMEN STREETTORRANCECA90503330554737RENTAL REAL ESTATECAN/A00
90210 ASC VENTURE LLC
450 N ROXBURY DR SUITE 602BEVERLY HILLSCA90210134341801AMBULATORY SURGERY CENTERCAN/A00
ABCENTRA LLC
2390 CRENSHAW BLVD 202TORRANCECA90501202327127RESEARCH AND DEVELOPMENTDEN/A00
TIA-CEDARS MANAGEMENT SERVICES ORGANIZATION LLC
548 MARKET ST SUITE 45295SFCA94104884206382INVESTMENT IN HEALTHCARE SERVICESCAN/A00
K HEALTH-CEDARS MANAGEMENT SERVICES ORGANIZATION LLC
6500 WILSHIRE BLVD STE 2250LACA90048932305005HEALTHCARE MANAGEMENT SERVICESCAN/A00
PASADENA ASC VENTURE LLC
6500 WILSHIRE BLVD 19TH FLOORLOS ANGELESCA90048991582374AMBULATORY SURGERY CENTERCAN/A00

Id Related Org Txbl Corp Tr IdRelatedOrgTxblCorpTrGrp (7 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdDirect Controlling NADirectControllingNACdEntity TypeEntityTypeTxtControlled OrganizationControlledOrganizationIndAddress Line1ForeignAddress/AddressLine1TxtCityForeignAddress/CityNmProvince Or StateForeignAddress/ProvinceOrStateNmCountryForeignAddress/CountryCdLegal Domicile Foreign CountryLegalDomicileForeignCountryCdForeign PostalForeignAddress/ForeignPostalCd
OPTIMATRIX HEALTH SOLUTIONS INC
8700 BEVERLY BLVDLOS ANGELESCA90048954522779INACTIVECAN/ACYes (1)
CONGRESS SERVICES CORPORATION
100 WEST CALIFORNIA BLVDPASADENACA91105953978299MANAGEMENT SERVICESCAN/ACYes (1)
GRAVIDAS DIAGNOSTICS INC
700 N SAN VICENTE BLVD SUITE G-700WEST HOLLYWOODCA90069872085657MEDICAL EQUIPMENT AND SUPPLIES MANUFACTURINGDEN/ACYes (1)
THIRD STREET INSURANCE COMPANY (SAC) LTD
981678749CAPTIVE INSURANCEN/ACYes (1)PO BOX HM 1024HAMILTONHM DXBDBD
LIQUID LOAN OPPORTUNITIES FUND LP
980693063INVESTMENTSN/ACYes (1)PO BOX 309UGLAND HOUSEGRAND CAYMANCJCJKY1-1104
CORONET VENTURES (SINGAPORE) PTE LTD
HEALTHCARE AND BIOMEDICAL INNOVATION INVESTMENTSN/ACYes (1)112 ROBINSON ROAD 04-02ROBINSONSINGAPORESNSN068902
CEDARS-SINAI UK LTD
CLINIC OPERATORN/ACYes (1)66 LINCOLNS INN FIELDSLONDONUKUKWC2A 3LH
FieldValueIRS element (for citing)
Receipt Of Int Annts Rnts Rylts0ReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth Org0GiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth OrgYes (1)GiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other Org0LoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth Org0LoansOrGuaranteesFromOthOrgInd
Div Related Organization0DivRelatedOrganizationInd
Asset Sale To Other Org0AssetSaleToOtherOrgInd
Asset Purchase From Other Org0AssetPurchaseFromOtherOrgInd
Asset Exchange0AssetExchangeInd
Rental Of Facilities To Oth Org0RentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth Org0RentalOfFcltsFromOthOrgInd
Perform Of Services For Oth Org0PerformOfServicesForOthOrgInd
Perform Of Services By Other Org0PerformOfServicesByOtherOrgInd
Sharing Of FacilitiesYes (1)SharingOfFacilitiesInd
Paid Employees SharingYes (1)PaidEmployeesSharingInd
Reimbursement Paid To Other OrgYes (1)ReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other Org0ReimbursementPaidByOtherOrgInd
Transfer To Other Org0TransferToOtherOrgInd
Transfer From Other Org0TransferFromOtherOrgInd

Transactions Related Org TransactionsRelatedOrgGrp

Other Organization Name OtherOrganizationName

FieldValueIRS element (for citing)
Business Name Line1CEDARS-SINAI MEDICAL CARE FOUNDATIONBusinessNameLine1Txt
FieldValueIRS element (for citing)
Transaction TypeNTransactionTypeTxt
Involved$1,948,597InvolvedAmt
Method Of Amount DeterminationFAIR MARKET VALUEMethodOfAmountDeterminationTxt

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.